Article
Cell Biology
Marjan Golabi, Farshid Fathi, Morteza Samadi, Mohammad Sadegh Hesamian, Nahid Eskandari
Summary: This study evaluated different miRNAs in RRMS patients compared to healthy controls and their correlations with altered T regulatory type 1 (Tr1) cells, osteopontin (OPN), and interleukin 10 (IL-10) levels. The results showed that Tr1 cells' frequency, Let7c-5p, and miR-299-5p levels decreased in RRMS patients, while miR-106a-5p levels increased. There was also a negative association between Tr1 frequency and plasma-OPN levels in RRMS patients, as well as a positive correlation between plasma-IL-10 and miR-299-5p expression.
Article
Clinical Neurology
Eva M. Strijbis, Eline Coerver, Jop Mostert, Zoe L. E. van Kempen, Joep Killestein, Jacynthe Comtois, Pavle Repovic, James D. Bowen, Gary Cutter, Marcus Koch
Summary: This study investigates the association between age and inflammatory disease activity in relapsing-remitting multiple sclerosis (RRMS) using patient-level data from randomized controlled trials (RCTs) of natalizumab treatment. The results show that older age is associated with lower prevalence and degree of focal inflammatory disease activity in treated and untreated RRMS patients. These findings provide important insights for the design of RCTs and the decision-making process of immunomodulatory treatment in RRMS.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2023)
Article
Clinical Neurology
Alyssa A. Toorop, Zoe Y. G. J. van Lierop, Liza M. Y. Gelissen, Elske Hoitsma, Esther M. P. E. Zeinstra, Luuk C. van Rooij, Caspar E. P. van Munster, Anke Vennegoor, Jop P. Mostert, Beatrijs H. A. Wokke, Nynke F. Kalkers, Erwin L. J. Hoogervorst, Jeroen J. J. van Eijk, Christiaan M. Roosendaal, Jolijn J. Kragt, Marijke Eurelings, Jessie van Genugten, Jessica Nielsen, Lgf Sinnige, Mark E. Kloosterziel, Edo P. J. Arnoldus, Gert W. van Dijk, Willem H. Bouvy, Mark H. J. Wessels, Lynn Boonkamp, Eva M. M. Strijbis, Bob W. van Oosten, Brigit A. De Jong, Birgit Lissenberg-Witte, Frederik Barkhof, Bastiaan Moraal, Charlotte E. Teunissen, Theo Rispens, Bernard M. J. Uitdehaag, Joep Killestein, Zoe L. E. van Kempen
Summary: Personalized extended interval dosing of natalizumab effectively controls disease activity in multiple sclerosis and can safely extend treatment intervals through therapeutic drug monitoring.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2023)
Letter
Clinical Neurology
Harald Kropshofer, Dieter A. Haering, Ludwig Kappos, David Leppert, Jens Kuhle
Summary: The results of this study contradict with earlier large phase 3 studies, suggesting that high baseline serum neurofilament light chain levels are associated with increased risk of disability progression in MS. The authors hypothesize that this discrepancy may be due to the anti-inflammatory effects of natalizumab, which suppresses inflammatory activity and renders sNfL unrelated to disability progression.
Article
Medicine, General & Internal
Martha Rocio Hernandez-Preciado, Jazmin Marquez-Pedroza, Nayeli Alejandra Sanchez-Rosales, Jose de Jesus Garcia-Rivera, Antonio Kobayashi-Gutierrez, Blanca Miriam Torres-Mendoza, Efrain Chavarria-Avila, Raul Alejandro Montano-Serrano, Fernando Cortes-Enriquez, Mario Alberto Mireles-Ramirez
Summary: This study evaluates the clinical files of RRMS patients and compares the effectiveness of rituximab with second-line treatments. The results show that rituximab has significant benefits in improving EDSS scores and reducing relapse rates.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Neurosciences
Maria-Eleftheria Evangelopoulos, Georgios Koutsis, Fotini Boufidou, Manolis Markianos
Summary: Cholesterol levels may be associated with disease characteristics in multiple sclerosis, particularly with demyelination and immune response. This study found lower levels of plasma and cerebrospinal fluid cholesterol in patients with multiple sclerosis. Patients with positive oligoclonal bands had even lower cerebrospinal fluid cholesterol levels, which may be related to disease progression and enhanced humoral immune response.
NEUROBIOLOGY OF DISEASE
(2022)
Article
Clinical Neurology
Cavit Boz, Serkan Ozakbas, Murat Terzi, Rana Karabudak, Serhan Sevim, Recai Turkoglu, Aysun Soysal, Belgin Petek Balci, Husnu Efendi, Omer Faruk Turan, Nur Yuceyar, Mehmet Fatih Yetkin, Serap Zengin Karahan, Meltem Demirkiran, Sibel Guler, Kadriye Agan, Nefati Kiylioglu, Cavid Baba, Asli Tuncer, Mesrure Koseoglu
Summary: This study compared the efficacy of three drugs (fingolimod, natalizumab, and ocrelizumab) in reducing disease activity in RRMS. The results showed that natalizumab and ocrelizumab had similar effects on relapse control, and both were better than fingolimod. The three therapies had similar effects on disability outcomes.
NEUROLOGICAL SCIENCES
(2023)
Article
Immunology
Igal Rosenstein, Sofia Rasch, Markus Axelsson, Lenka Novakova, Kaj Blennow, Henrik Zetterberg, Jan Lycke
Summary: This study suggests that determination of intrathecal immunoglobulin M synthesis (ITMS) and neurofilament light concentration in cerebrospinal fluid (CSF) can be useful biomarkers for predicting disease severity and disability in relapsing-remitting multiple sclerosis (RRMS). The combination of ITMS with CSF neurofilament light (cNfL) shows a stronger predictive value.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Clinical Neurology
S. Grahl, M. Bussas, B. Wiestler, P. Eichinger, C. Gaser, J. Kirschke, C. Zimmer, A. Berthele, B. Hemmer, M. Muehlau
Summary: This study compared the effects of Fingolimod and Natalizumab in treating relapsing-remitting multiple sclerosis, finding that Fingolimod treatment led to more new white matter lesions but lower overall brain atrophy. The results support the notion that Fingolimod has stronger neuroprotective properties compared to Natalizumab.
Article
Clinical Neurology
Fabien Rollot, Justine Couturier, Romain Casey, Sandrine Wiertlewski, Marc Debouverie, Jean Pelletier, Jerome De Seze, Pierre Labauge, Aurelie Ruet, Eric Thouvenot, Jonathan Ciron, Eric Berger, Olivier Gout, Pierre Clavelou, Bruno Stankoff, Olivier Casez, Bertrand Bourre, Helene Zephir, Thibault Moreau, Christine Lebrun-Frenay, Elisabeth Maillart, Gilles Edan, Jean-Philippe Neau, Alexis Montcuquet, Philippe Cabre, Jean-Philippe Camdessanche, Gilles Defer, Haifa Ben Nasr, Aude Maurousset, Karolina Hankiewicz, Corinne Pottier, Emmanuelle Leray, Sandra Vukusic, David-Axel Laplaud
Summary: This study compared the effectiveness of NTZ and anti-CD20 as a switch for FNG in highly active RRMS patients in France. The results showed no difference between the two treatments regarding the first occurrence of relapse, EDSS worsening, and MRI activity. However, there was a higher risk of treatment discontinuation with NTZ compared to anti-CD20.
Article
Health Care Sciences & Services
Mehdi Rezaee, Mohammad Hossein Morowvat, Maryam Poursadeghfard, Armin Radgoudarzi, Khosro Keshavarz
Summary: This study aimed to evaluate the cost-effectiveness of rituximab compared to natalizumab in RRMS patients in southern Iran in 2020. The results showed that rituximab had lower treatment costs, higher effectiveness, and lower relapse rates compared to natalizumab. Therefore, rituximab can be considered a more cost-effective option for RRMS patients.
BMC HEALTH SERVICES RESEARCH
(2022)
Article
Clinical Neurology
Massimo Filippi, Luigi Grimaldi, Antonella Conte, Rocco Totaro, Maria Rosaria Valente, Simona Malucchi, Franco Granella, Cinzia Cordioli, Vincenzo Brescia Morra, Chiara Zanetta, Daria Perini, Laura Santoni, EASIER Study Working Grp
Summary: The EASIER study investigates the consumption of healthcare resources and associated costs of natalizumab administration. The study finds that adopting the subcutaneous route can significantly reduce patient and healthcare professional time and costs.
JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Igal Rosenstein, Markus Axelsson, Lenka Novakova, Clas Malmestroem, Kaj Blennow, Henrik Zetterberg, Jan Lycke
Summary: While KFLC index is a useful diagnostic biomarker in multiple sclerosis (MS), its prognostic properties are less explored. This study found that high baseline KFLC index is predictive of PIRA, evidence of disease activity (EDA-3), and overall worse prognosis in MS.
JOURNAL OF NEUROLOGY
(2023)
Article
Medicine, Research & Experimental
Jai Perumal, Roumen Balabanov, Ray Su, Roger Chang, Laura Balcer, Steven Galetta, Denise I. Campagnolo, Robin Avila, Lily Lee, Danette Rutledge, Robert J. Fox
Summary: The STRIVE study demonstrates that natalizumab treatment is effective in reducing disease activity in early relapsing-remitting multiple sclerosis patients, with good long-term safety and efficacy. Baseline factors such as age and brain MRI abnormalities can predict whether patients will achieve no evidence of disease activity status.
ADVANCES IN THERAPY
(2021)
Article
Neurosciences
Xingwei Fang, Yaxin Lu, Yongmei Fu, Zifeng Liu, Allan G. Kermode, Wei Qiu, Li Ling, Chunxin Liu
Summary: This study investigated the association between routine cerebrospinal fluid (CSF) findings, especially CSF chloride, at the time of the first lumbar puncture and the relapse risk and disability progression of relapsing-remitting multiple sclerosis (RRMS). The study found that elevated CSF chloride levels were associated with a higher risk of MS relapse.
Article
Clinical Neurology
Johanna Balslev Andersen, Finn Sellebjerg, Melinda Magyari
Summary: This study found no increased association of adverse pregnancy outcomes in newborns with fetal exposure to disease-modifying drugs (DMDs) when compared with either DMD-unexposed pregnancies or the general population.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Genetics & Heredity
Florence Thirion, Finn Sellebjerg, Yong Fan, Liwei Lyu, Tue H. Hansen, Nicolas Pons, Florence Levenez, Benoit Quinquis, Evelina Stankevic, Helle B. Sondergaard, Thomas M. Dantoft, Casper S. Poulsen, Sofia K. Forslund, Henrik Vestergaard, Torben Hansen, Susanne Brix, Annette Oturai, Per Soelberg Sorensen, Stanislav D. Ehrlich, Oluf Pedersen
Summary: This study found significant differences in the gut microbiota of patients with multiple sclerosis, which are directly associated with inflammation markers. In treatment-naive cases, the bacterial richness is positively linked to disease activity. However, two symbiotic bacterial species that produce beneficial immune-modulating compounds were found in non-disease-active cases, providing a rationale for testing these bacteria as adjunct therapeutics in future clinical trials.
Article
Neurosciences
Kristian Steen Frederiksen, Camilla Steen Jensen, Peter Hogh, Robert Gergelyffy, Gunhild Waldemar, Birgitte Bo Andersen, Hanne Gottrup, Karsten Vestergaard, Lene Wermuth, Helle Bach Sondergaard, Finn Sellebjerg, Steen Gregers Hasselbalch, Anja Hviid Simonsen
Summary: This study aimed to investigate whether a 16-week aerobic exercise program could reduce serum NfL in patients with mild Alzheimer's disease. The results showed that the exercise intervention did not have a significant effect on neurodegeneration. Further studies are needed to explore other types and durations of exercise as well as other measures of neurodegeneration.
FRONTIERS IN NEUROSCIENCE
(2023)
Article
Clinical Neurology
Per Soelberg Sorensen, Luigi Pontieri, Hanna Joensen, Alex Heick, Peter Vestergaard Rasmussen, Jakob Schafer, Rikke Ratzer, Caroline Ellinore Pihl, Finn Sellebjerg, Melinda Magyari
Summary: Cladribine is an effective treatment for relapsing multiple sclerosis by reducing lymphocyte levels, especially B-cells. This real-world study in Denmark examined the treatment patterns and outcomes of cladribine therapy, finding it to be safe and effective in line with previous clinical trials.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2023)
Article
Clinical Neurology
Rolf Pringler Holm, Luigi Pontieri, Malthe Faurschou Wandall-Holm, Elisabeth Framke, Finn Sellebjerg, Melinda Magyari
Summary: This study aimed to determine the period of diagnostic uncertainty among Danish MS patients and examine the performance of two objective classifiers in shortening the period. The results showed a median period of diagnostic uncertainty of 2.12 years. The current objective classifiers did not perform satisfactorily in predicting transition dates, but they have the potential to help reduce the period of diagnostic uncertainty in the future.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2023)
Article
Clinical Neurology
Jacob Talbot, Henrik Lundell, Lisbet Marstrand, Camilla Gobel Madsen, Malene Bredahl Hansen, Hartwig Roman Siebner, Finn Sellebjerg, Helene Hojsgaard Chow, Helle Bach Sondergaard, Per Solberg Sorensen
Summary: In the open-label extension phase of the trial, treatment with dimethyl fumarate did not show any significant effects on clinical or MRI outcomes, as well as serum concentrations of NFL. A relatively equal number of patients showed evidence of progression and improvement, raising questions for future studies.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2023)
Article
Clinical Neurology
Heinz Wiendl, Klaus Schmierer, Suzanne Hodgkinson, Tobias Derfuss, Andrew Chan, Finn Sellebjerg, Anat Achiron, Xavier Montalban, Alexandre Prat, Nicola De Stefano, Frederik Barkhof, Letizia Leocani, Patrick Vermersch, Anita Chudecka, Claire Mwape, Kristina H. Holmberg, Ursula Boschert, Sanjeev Roy, MAGNIFY-MS Study Grp
Summary: Cladribine tablets cause a reduction in lymphocytes, with a predominant effect on B-cell and T-cell counts. The MAGNIFY-MS substudy reports the dynamic changes on multiple peripheral blood mononuclear cell (PBMC) subtypes and immunoglobulin (Ig) levels over 12 months after the first course of cladribine tablets in patients with highly active relapsing multiple sclerosis (MS).
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION
(2023)
Article
Clinical Neurology
Rikke Holm Hansen, Marina Rode von Essen, Mie Reith Mahler, Stefan Cobanovic, Tomas Sorm Binko, Finn Sellebjerg
Summary: ObjectiveCladribine tablet therapy is effective for multiple sclerosis (MS), but its mechanism on T and B cell subsets remains unclear. This study investigated the effects of cladribine on T and B cell subsets and reactivity towards central nervous system (CNS) antigens. The results showed that cladribine treatment reduced CD4(+) T cells but normalized CD19(+) B cells. Additionally, the peripheral B cell pool had a more naive and anti-inflammatory phenotype and there was reduced reactivity to the CNS antigen RASGRP2 in treated patients.
ANNALS OF NEUROLOGY
(2023)
Article
Clinical Neurology
Anja Sofie Petersen, Mads Barloese, Nunu Lund, Adam Friis Pedersen, Marie-Louise Kulas Soborg, Mona Ameri Chalmer, Ida Callesen, Bendik Slagsvold Winsvold, John-Anker Zwart, Sisse Rye DBDS Genomic Consortium, Sisse Rye Ostrowski, Ole Birger Pedersen, Finn Sellebjerg, Helle Bach Sondergaard, Malene Bredahl Hansen, Rigmor Hojland Jensen, Thomas Folkmann Hansen
Summary: This study investigated the association between polygenetic risk, functional variants of CYP3A4, and treatment response in cluster headache patients. The results showed that the response to oxygen, triptans, and verapamil was associated with the chronicity of cluster headache, but not with a high genetic risk. The response to verapamil was also not influenced by functional variants of CYP3A4. Furthermore, no support was found for the genetic variants previously reported to be associated with treatment response. Overall, this study suggests that the clinically relevant variation in treatment response in cluster headache is not influenced by genetic factors.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Stefan Gustavsen, Anna Olsson, Annette B. Oturai, Kristian Linnet, Ragnar Thomsen, Brian S. Rasmussen, Christian F. Jorgensen, Annika R. Langkilde, Per S. Sorensen, Finn Sellebjerg, Helle B. Sondergaard
Summary: This study aimed to compare the alteration of the endocannabinoid system (ECS) in newly diagnosed multiple sclerosis (MS) patients and healthy controls (HCs). The results showed no differences in the gene expression or plasma levels of ECS components between the two groups. Therefore, the ECS has a minor overall involvement in the regulation of inflammatory markers and clinical parameters in the early stage of MS.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Multidisciplinary Sciences
Olivia G. Thomas, Mattias Bronge, Katarina Tengvall, Birce Akpinar, Ola B. Nilsson, Erik Holmgren, Tara Hessa, Guro Gafvelin, Mohsen Khademi, Lars Alfredsson, Roland Martin, Andre Ortlieb Guerreiro-Cacais, Hans Groenlund, Tomas Olsson, Ingrid Kockum
Summary: Multiple sclerosis (MS) is an inflammatory disease of the central nervous system, with Epstein-Barr virus (EBV) infection as a likely prerequisite. This study found that antibody reactivity to CRYAB amino acids 7 to 16 was associated with MS, and the combination of high EBNA1 responses with CRYAB positivity greatly increased disease risk. Additionally, evidence of antibody cross-reactivity between EBNA1 and CRYAB, as well as T cell cross-reactivity, was found, further demonstrating the role of EBV immune responses in MS development.
Article
Immunology
Maria Teresa Martin Monreal, Bjarke E. Hansen, Pernille F. Iversen, Christian Enevold, Niels Odum, Finn Sellebjerg, Peter Hojrup, Marina Rode von Essen, Claus H. Nielsen
Summary: The research suggests that citrullination, a post-translational modification, may play a role in the development of multiple sclerosis (MS). The autoimmune response to myelin basic protein (MBP) is enhanced when it is hypercitrullinated in MS patients. In addition, citMBP binds more effectively to HLA-DR15, which is associated with MS, compared to native MBP. These findings point to the importance of citrullination in breaching tolerance to MBP and maintaining the autoimmune response in MS patients.
JOURNAL OF AUTOIMMUNITY
(2023)
Article
Immunology
Sahla El Mahdaoui, Signe Refstrup Husted, Malene Bredahl Hansen, Stefan Cobanovic, Mie Reith Mahler, Sophie Buhelt, Marina Rode von Essen, Finn Sellebjerg, Jeppe Romme Christensen
Summary: Cerebrospinal fluid (CSF) soluble CD27 (sCD27) is a sensitive biomarker of intrathecal inflammation, and it has been found to be correlated with B cell activity in multiple sclerosis (MS). In this study, CSF samples from RRMS patients and symptomatic controls were analyzed using flow cytometry and multiplex electrochemiluminescence immunoassays. Results showed that CSF sCD27 levels were increased in RRMS and correlated with various factors, including IgG index, soluble B cell maturation antigen, cell count, B cell frequency, and CD8+ T cell frequency. These findings suggest that CSF sCD27 is associated with CD8+ T cells and B cells in RRMS.
JOURNAL OF NEUROIMMUNOLOGY
(2023)
Article
Chemistry, Medicinal
Julie Schjodtz Hansen, Stefan Gustavsen, Homayoun Roshanisefat, Matthias Kant, Fin Biering-Sorensen, Claus Andersen, Anna Olsson, Helene Hojsgaard Chow, Nasrin Asgari, Julie Richter Hansen, Helle Hvilsted Nielsen, Rikke Middelhede Hansen, Thor Petersen, Annette Bang Oturai, Finn Sellebjerg, Eva Aggerholm Saedder, Helge Kasch, Peter Vestergaard Rasmussen, Nanna Brix Finnerup, Kristina Bacher Svendsen
Summary: This study investigated the effect of cannabis-based medicine (CBM) on central neuropathic pain (NP) and spasticity in patients with multiple sclerosis (MS) and spinal cord injury (SCI). The results showed that THC, CBD, or their combination did not have a significant effect on pain and spasticity. The study was limited by a smaller sample size due to COVID-19 and recruitment challenges.
Review
Clinical Neurology
Per Soelberg Sorensen, Melinda Magyari, Finn Sellebjerg
Summary: The combination of two platform therapies for multiple sclerosis did not have additional effect. Add-on therapies with repurposed drugs have been negative, except for monthly methylprednisolone which had low tolerability. Combination therapy for neuroprotection/remyelination showed some interesting results, but awaits phase III trial results. The combination of new effective neuroprotective/remyelinating drugs and highly effective anti-inflammatory treatments may benefit people with MS.
EXPERT REVIEW OF NEUROTHERAPEUTICS
(2023)
